Sona Nanotech Inc.

Recent News

  • Sona Discontinues Clinical Trial for COVID-19 Rapid Saliva Test

    - Encouraging analytical test results did not translate to an ability to consistently detect the virus in clinical samples - Company will focus resources on advancement of other rapid tests and further research with its proprietary gold nanorod technology Halifax, Nova Scotia--(Newsfile Corp. - June 11, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that it is discontinuing its previously announced clinical trial of its COVID-19 rapid, antigen saliva...

    2021-06-11 8:43 AM EDT
  • Sona Nanotech Approved for Funding Support to Develop a Bovine Tuberculosis Rapid Test

    Halifax, Nova Scotia--(Newsfile Corp. - May 20, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it is receiving advisory services and up to $457,830 in funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research project in association with a consortium of UK companies to develop a bovine tuberculosis ("bTB") rapid test. NRC IRAP's...

    2021-05-20 9:00 AM EDT
  • Sona to Commence Clinical Trial for COVID-19 Rapid Saliva Test

    Halifax, Nova Scotia--(Newsfile Corp. - April 22, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has received research ethics board approval for its clinical trial of the Sona Saliva C-19 Rapid Test. The trial, which will seek to test up to 500 emergency room patients suspected of having COVID-19, is expected to commence next week. The Company will update the market...

    2021-04-22 4:50 PM EDT
  • Sona Secures Clinical Trial Authorization and Hospital Partner

    Halifax, Nova Scotia--(Newsfile Corp. - April 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final ethics review board sign-off of...

    2021-04-12 9:13 PM EDT
  • Sona Establishes an At-The-Market Common Share Offering

    Halifax, Nova Scotia--(Newsfile Corp. - April 9, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that pursuant to an equity distribution agreement (the "Equity Distribution Agreement") with Canaccord Genuity Corp., the Company may, from time to time, sell up to $10 million of common shares ("Common Shares") in the capital of the Company (the "ATM Offering"). The Company intends to use the net proceeds of the...

    2021-04-09 7:53 PM EDT
  • Sona Announces Filing of Preliminary Short Form Base Shelf Prospectus

    Halifax, Nova Scotia--(Newsfile Corp. - March 23, 2021) -  Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests, has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The objective of filing the Shelf Prospectus is to provide the Company with the financial flexibility to take advantage of financing opportunities and favourable market conditions, if...

    2021-03-23 4:11 PM EDT
  • Sona Nanotech Receives CE Mark Approval for its Rapid COVID-19 Antigen Test

    Halifax, Nova Scotia--(Newsfile Corp. - December 31, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, has been granted CE Mark status for its rapid, COVID-19 antigen test. The CE Mark declares the conformity of the Sona test with EU regulations and allows Sona to commercialize its test throughout Europe and potentially other territories in which the CE Mark is recognized.The Company intends to begin selling its test as...

    2020-12-31 9:08 AM EST
  • Sona Nanotech Closes Unbrokered Private Placement Financing for $2.26M in Gross Proceeds

    Halifax, Nova Scotia--(Newsfile Corp. - December 16, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company", "Sona") a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has closed its non-brokered private placement that was announced on December 3, 2020 with the issuance of 2,259,200 units at $1.00 per unit.The final amount of the offering represents an increase from the Company's previously announced intention to raise up to $2,000,000 through a non-brokered private placement...

    2020-12-16 9:32 AM EST